PATH | VRL
Menu

Efficacy of a Monovalent Human-Bovine (116E) Rotavirus Vaccine in Indian Infants: A Randomised, Double-Blind, Placebo-Controlled Trial

This article, published in The Lancet, reports on the results of a Phase 3 study to assess the efficacy and tolerability of a monovalent human-bovine rotavirus vaccine (116E) for severe rotavirus gastroenteritis in low-resource urban and rural settings in India. The study results indicated that the 116E rotavirus vaccine is effective and well tolerated among Indian infants. Vaccine efficacy against severe rotavirus gastroenteritis was found to be 56.4 percent in the first year of life.

Author: Bhandari N, Rongsen-Chandola T, Bavdekar A, et al.

Published: 2014

» Visit web page (English)

(Located at www.thelancet.com)

Citation: Bhandari N, Rongsen-Chandola T, Bavdekar A, et al. Efficacy of a Monovalent Human-Bovine (116E) Rotavirus Vaccine in Indian Infants: A Randomised, Double-Blind, Placebo-Controlled Trial. The Lancet. 2014;383(9935):2136-2143.

Resource types: Peer-reviewed journal

Diseases/vaccines: Rotavirus

Topics: Vaccine safety and performance, Disease/vaccine specific information

Regions: Asia